<H1>Chapter DOI: 10.1007/978-1-60327-829-4_18<br/>Cited-By Count: 1</H1><table border="1" width="30%"><tr><td>Total References</td><td>45</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>44</td></tr><tr><td>BibStructured Count</td><td width="10%">45</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>32</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_18</td><td>BibArticle</td><td>Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669&#8211;76.</td><td><a href=http://dx.doi.org/10.1038/nm0603-669>10.1038/nm0603-669</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_18</td><td>BibArticle</td><td>Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841&#8211;4.</td><td><a href=http://dx.doi.org/10.1038/362841a0>10.1038/362841a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_18</td><td>BibArticle</td><td>Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/0092-8674(94)90187-2>10.1016/0092-8674(94)90187-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_18</td><td>BibArticle</td><td>Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182&#8211;6.</td><td><a href=http://dx.doi.org/10.1056/NEJM197108122850711>10.1056/NEJM197108122850711</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_18</td><td>BibArticle</td><td>Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409&#8211;16.</td><td><a href=http://dx.doi.org/10.1097/00000658-197203000-00014>10.1097/00000658-197203000-00014</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_18</td><td>BibArticle</td><td>Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 1975;82:96&#8211;100.</td><td><a href=http://dx.doi.org/10.7326/0003-4819-82-1-96>10.7326/0003-4819-82-1-96</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_18</td><td>BibArticle</td><td>Wray CJ, Rilo HL, Ahmad SA. Colon cancer angiogenesis and antiangiogenic therapy. Expert Opin Investig Drugs 2004;13:631&#8211;41.</td><td><a href=http://dx.doi.org/10.1517/13543784.13.6.631>10.1517/13543784.13.6.631</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_18</td><td>BibArticle</td><td>Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995;154:69&#8211;71.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)67230-6>10.1016/S0022-5347(01)67230-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_18</td><td>BibArticle</td><td>Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;340:145&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/0140-6736(92)93217-B>10.1016/0140-6736(92)93217-B</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_18</td><td>BibArticle</td><td>Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875&#8211;87.</td><td><a href=http://dx.doi.org/10.1093/jnci/84.24.1875>10.1093/jnci/84.24.1875</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_18</td><td>BibArticle</td><td>Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis &#8211; correlation in invasive breast carcinoma. N Engl J Med 1991;324:1&#8211;8.</td><td><a href=http://dx.doi.org/10.1056/NEJM199101033240101>10.1056/NEJM199101033240101</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_18</td><td>BibArticle</td><td>Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13_18</td><td>BibArticle</td><td>Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75:2545&#8211;51.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(19950515)75:10&lt;2545::AID-CNCR2820751022&gt;3.0.CO;2-X>10.1002/1097-0142(19950515)75:10&lt;2545::AID-CNCR2820751022&gt;3.0.CO;2-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_18</td><td>BibArticle</td><td>Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001;86:23&#8211;33.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15_18</td><td>BibArticle</td><td>Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13:31&#8211;6.</td><td><a href=http://dx.doi.org/10.1002/bies.950130106>10.1002/bies.950130106</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_18</td><td>BibArticle</td><td>Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671&#8211;80.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_18</td><td>BibArticle</td><td>Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58&#8211;62.</td><td><a href=http://dx.doi.org/10.1126/science.1104819>10.1126/science.1104819</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_18</td><td>BibArticle</td><td>Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than antiangiogenic. Cancer Metastasis Rev 2007;26:443&#8211;52.</td><td><a href=http://dx.doi.org/10.1007/s10555-007-9071-1>10.1007/s10555-007-9071-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_18</td><td>BibArticle</td><td>Ferrara N. Role of vascular endothelial growth factor in regulation of angiogenesis. Kidney Int 1999;56:794&#8211;814.</td><td><a href=http://dx.doi.org/10.1046/j.1523-1755.1999.00610.x>10.1046/j.1523-1755.1999.00610.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_18</td><td>BibArticle</td><td>Ferrara N and Davis-Smyth T. The biology of vascular endothelial growth factor. Endrocrinology 1997;18:1&#8211;22.</td><td><a href=http://dx.doi.org/10.1210/edrv.18.1.0287>10.1210/edrv.18.1.0287</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, ArticleTitle, Author_FamilyName_1, VolumeID</td><td>CrossRef</td></tr><tr><td>CR21_18</td><td>BibArticle</td><td>Ferrer FA, Miller LJ, et al. Expression of vascular endothelial receptors inhuman prostate cancer. Urology 1999;43:567&#8211;72.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(99)00156-9>10.1016/S0090-4295(99)00156-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_18</td><td>BibArticle</td><td>Ferrer FA, Miller LJ, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of FEGG by human prostate cancer cells. J Urol 1997;157:2329&#8211;33.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)64775-X>10.1016/S0022-5347(01)64775-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_18</td><td>BibArticle</td><td>Duque J, Loughlin K, et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;45:523&#8211;27.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(99)00167-3>10.1016/S0090-4295(99)00167-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_18</td><td>BibArticle</td><td>Duque JL, Loughlin KR, et al. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics 2006;61(5):401&#8211;8.</td><td><a href=http://dx.doi.org/10.1590/S1807-59322006000500006>10.1590/S1807-59322006000500006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_18</td><td>BibArticle</td><td>Bok R, Halabi S, et al. VEGF and bFGF urine levels as predictors of outcome in hormone refractory prostate cancer patients: a CALGB study. Cancer Res 2001;61:2533&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26_18</td><td>BibArticle</td><td>George D, Halabi S, et al. Prognostic significance of plasma vascular endothelial growth factor (VEGF) levels in patients with hormone refractory prostate cancer: a CALGB study. Clin Cancer Res 2001;7:1932&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR27_18</td><td>BibArticle</td><td>Joseph IBJK, Nelson JB, et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostate tissues. Clin Cancer Res 1997;3:2507&#8211;11.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28_18</td><td>BibArticle</td><td>Jain A, Safabakhsh N, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1998;95:10820&#8211;25.</td><td><a href=http://dx.doi.org/10.1073/pnas.95.18.10820>10.1073/pnas.95.18.10820</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_18</td><td>BibArticle</td><td>Kirschenbaum A, Wang J, et al. Inhibition of vascular endothelial cell growth factor suppresses the in vitro growth of human prostate cancer tumors. Urol Oncol 1997;3:3&#8211;10.</td><td><a href=http://dx.doi.org/10.1016/S1078-1439(97)00001-X>10.1016/S1078-1439(97)00001-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_18</td><td>BibArticle</td><td>Borgstrom P, Bourdon M, et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro-tumors in vivo. Prostate 1998;35:1&#8211;10.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0045(19980401)35:1&lt;1::AID-PROS1&gt;3.0.CO;2-O>10.1002/(SICI)1097-0045(19980401)35:1&lt;1::AID-PROS1&gt;3.0.CO;2-O</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_18</td><td>BibArticle</td><td>Melynk O, Simmerman M, et al. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in pre-clinical model. J Urol 1999;161:960&#8211;63.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)61829-9>10.1016/S0022-5347(01)61829-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_18</td><td>BibArticle</td><td>Hammarsten P, Halin S, et al. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res 2006;12(24):7431&#8211;6.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-1895>10.1158/1078-0432.CCR-06-1895</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_18</td><td>BibArticle</td><td>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335&#8211;42.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa032691>10.1056/NEJMoa032691</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_18</td><td>BibBook</td><td>Giantonio BJ, Catalano PJ, Meropol NJ, O&#8217;Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO 2005 (abstract 2).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR35_18</td><td>BibArticle</td><td>Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542&#8211;50.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa061884>10.1056/NEJMoa061884</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_18</td><td>BibArticle</td><td>Miller K, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005;94(suppl 1):S6 (abstract 3).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR37_18</td><td>BibArticle</td><td>Presta LG, Chen H, O&#8217;Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593&#8211;99.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR38_18</td><td>BibArticle</td><td>Reese DM, Fratesi P, Corry M, et al. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate 2001;3:65&#8211;70.</td><td><a href=http://dx.doi.org/10.1046/j.1525-1411.2001.32007.x>10.1046/j.1525-1411.2001.32007.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_18</td><td>BibArticle</td><td>Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003;22:1578.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR40_18</td><td>BibArticle</td><td>Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 2001;19(9):2509&#8211;16.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR41_18</td><td>BibArticle</td><td>Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: cancer and Leukemia Group B 99813. Cancer 2003;98(12):2592&#8211;8.</td><td><a href=http://dx.doi.org/10.1002/cncr.11829>10.1002/cncr.11829</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42_18</td><td>BibArticle</td><td>Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008;54(5):1089&#8211;94.</td><td><a href=http://dx.doi.org/10.1016/j.eururo.2008.01.082>10.1016/j.eururo.2008.01.082</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_18</td><td>BibArticle</td><td>Ning YM, Gulley JL, Arlen PM, et al. A phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070&#8211;6.</td><td><a href=http://dx.doi.org/10.1200/JCO.2009.25.4524>10.1200/JCO.2009.25.4524</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_18</td><td>BibArticle</td><td>Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. ASCO Annual Meeting Proceedings J Clin Oncol 2010;28:LBA4511.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR46_18</td><td>BibArticle</td><td>Keating NL, O&#8217;Malley AJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448&#8211;56.</td><td><a href=http://dx.doi.org/10.1200/JCO.2006.06.2497>10.1200/JCO.2006.06.2497</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>